Drug intelligence / Profile preview

valsartan + indapamide

Development stage
Unknown
Lead developer
Apontis Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

ValsaInda is a fixed-dose combination (Single Pill) medication developed by Apontis Pharma for the treatment of hypertension. It combines two established antihypertensive agents: valsartan, an angiotensin II receptor blocker (ARB), and indapamide, a thiazide-like diuretic. Valsartan lowers blood pressure by selectively blocking the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and decreased aldosterone production. Indapamide acts on the distal convoluted tubules of the kidney to inhibit sodium reabsorption, thereby increasing water and salt excretion and reducing plasma volume. This combination therapy is intended to simplify treatment regimens and improve patient compliance in individuals whose blood pressure is not adequately controlled by monotherapy.

Brand names
ValsaIndaValsaInda APONTIS
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on valsartan + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valsartan + indapamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call